Neuracle Science Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2015-10-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.neuracles.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients
Phase 1
Recruiting
- Conditions
- Seneorineural DeafnessSudden Sensorineural Hearing Loss
- Interventions
- Biological: Placebo
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Neuracle Science Co., LTD.
- Target Recruit Count
- 118
- Registration Number
- NCT06249919
- Locations
- 🇰🇷
SCH University Hospital Bucheon, Bucheon, Korea, Republic of
🇰🇷Chonam National University Hospital, Gwangju, Korea, Republic of
🇰🇷Inje University Ilsan Paik Hospital, Ilsan, Korea, Republic of
A FIH Study to Assess the Safety and Tolerability of NS Intravenous NS101 Infusion
Phase 1
Completed
- Conditions
- Neurodegenerative Diseases
- Interventions
- Drug: NS101 IV infusion
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Neuracle Science Co., LTD.
- Target Recruit Count
- 64
- Registration Number
- NCT05143463
- Locations
- 🇨🇦
Syneos Health, Québec, Canada
News
No news found